Nā huahana

ʻO ka pahuhopu o kēia haʻawina ʻo ia ka hoʻohālikelike ʻana i ka maikaʻi o ka valproate versus haloperidol i ka hoʻohaʻahaʻa ʻana i ka pae haʻalulu i nā maʻi i hoʻopilikia ʻia i ka keʻena pilikia.Ua hāʻawi mākou i 80 mau maʻi hoʻonāukiuki loa e loaʻa i ka sodium valproate intravenous (20 mg/kg) a i ʻole intramuscular haloperidol (5 mg/1 ml).Ua anaʻia ka hoʻonāukiuki ma ka baseline a me 30 min ma hope o ka hoʻopiʻi muaʻana me ka hoʻohanaʻana i ka Agitation-Calmness Evaluation Scale (ACES), ka Positive and Negative Syndrome Scale-Excited Component subscale, a me ka Agitated Behavior Scale.No nā maʻi 80 i mālama ʻia me ka sodium valproate, ʻo ka mean ± SD ʻo 1541.5 ± 286 mg (mahele 940-2400).ʻO ka mean postintervention ACES helu mai ka baseline a hiki i ka 30 min ma hope o ka hoʻohana ʻana i ka lāʻau lapaʻau he 4.73 (SD = 1.93) no ka hui valproate a me 5.45 (SD = 2.09) no ka hui haloperidol (P = 0.028).ʻAʻole i ʻike ʻia nā ʻokoʻa koʻikoʻi ma ke ʻano o nā hoʻololi mean 30 min ma hope o ka hana ʻana no ʻelua mau unahi hoʻonāukiuki hou.ʻO ka hapa nui o nā maʻi i loko o ka hui haloperidol i ʻike i ka sedation ikaika (36.2%, P <0.001) a me nā hōʻailona extrapyramidal (8.7%, P = 0.007) i hoʻohālikelike ʻia me ka hui valproate (2.5% no ka sedation ikaika, ʻaʻohe mea maʻi no nā hōʻailona extrapyramidal).Hōʻike nā ʻike i ka hoʻomaʻamaʻa hoʻomaʻamaʻa hoʻomaʻamaʻa o ka psychiatry pilikia, ʻoi aku ka maikaʻi o ka valproate intravenous e like me ka haloperidol i ka hoʻohaʻahaʻa ʻana i ka hoʻonāukiuki, me ka ʻoi aku ka maikaʻi o ka palekana.